Can dipyridamole induce protection against ischemia and reperfusion injury in patients undergoing elective CABG?

Phase 4

Completed

• Conditions: heart attack; ischemia reperfusion injury; 10011082

• Registration Number: NL-OMON33210
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 130

Inclusion Criteria

- Acceptation for CABG in RUNMC
- Informed consent

Exclusion Criteria

- Recent myocardial infarction (STEMI or non-STEMI), during two weeks prior to
inclusion
- Asthma
- Use of insulin
- Use of sulfonylurea derivates (e.g. glibenclamide, tolbutamide, gliclazide, glimepiride)
- Use of metformin
- Use of oral corticosteroids
- Use of dipyridamole
- Use of clopidogrel within 8 days prior to scheduled CABG surgery
- Chronic use of Non Steroid Anti-Inflammatory Drugs (NSAIDs)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Troponin-I levels measured before and 6,12,24,48, and 72 hours after CABG.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Incidence of arrhythmias, need for prolonged inotropic support (longer than 24<br /><br>hours postoperative), prolonged ICU stay (longer than 24 hours). Biomarkers in<br /><br>renal injury (serum creatinine, KIM-1 and SELDI-TOF analysis of urinary<br /><br>samples).<br /><br>Post-ischemic recovery of contractile function in our atrial trabeculae model.</p><br>